Breaking News Instant updates and real-time market news.

SGYP

Synergy Pharmaceuticals

$5.68

-0.11 (-1.90%)

16:43
03/01/17
03/01
16:43
03/01/17
16:43

Synergy Pharmaceuticals reports Q4 EPS (31c), consensus (20c)

"The approval of TRULANCE in the United States for the treatment of adults with chronic idiopathic constipation was a tremendous event not just for Synergy, but also for the millions of patients with CIC who have been in need of a new therapeutic option," said Gary S. Jacob, PhD, Chairman and Chief Executive Officer of Synergy Pharmaceuticals Inc. "I am pleased with the progress our team has made implementing a strong and compelling commercial plan, a robust high quality supply chain, and ensuring that the Synergy organization, healthcare providers and payers, are well prepared for the launch of TRULANCE this month. In addition, we are continuing our efforts to bring TRULANCE to patients with irritable bowel syndrome with constipation, as we remain on-track to file a supplemental new drug application this month."

  • 21

    Mar

SGYP Synergy Pharmaceuticals
$5.68

-0.11 (-1.90%)

01/23/17
ROTH
01/23/17
NO CHANGE
Target $10.5
ROTH
Buy
Synergy Pharmaceuticals price target raised to $10.50 from $6.50 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Synergy Pharmaceuticals (SGYP) to $10.50 from $6.50 after the FDA approved Trulance for the treatment of adults with chronic idiopathic constipation, and due to Synergy Pharmaceuticals lowered risk profile and to better align with the valuation of its peer Ironwood Pharmaceuticals (IRWD). He reiterates a Buy rating on Synergy Pharmaceuticals' shares.
02/22/17
PIPR
02/22/17
NO CHANGE
Target $205
PIPR
Neutral
Piper physician survey a 'mixed bag' for Allergan's Linzess
Piper Jaffray analyst David Amsellem says his firm's survey of 39 physicians is a "mixed bag" for Allergan's (AGN) Linzess. The feedback from doctors suggest that the prospects for double-digit annual volume growth for Linzess over the long-term "are not nearly as strong as sentiment in the broader investor community would suggest," Amsellem tells investors in a research note. A bulk of the respondents have a favorable view of Linzess but also "misgivings regarding the incidence of diarrhea," the analyst adds. Further, Amsellem does not conclude that Synergy Pharmaceuticals' (SGYP) recently approved Trulance in chronic idiopathic constipation is the "poor man's Lizness." The lower incidence of diarrhea associated with Trulance does not necessarily mean that it is a less potent agent, the analyst contends. He keeps a Neutral rating on Allergan with a $205 price target.
02/22/17
WELS
02/22/17
NO CHANGE
WELS
Underperform
Wells thinks 50-plus salespeople just left Valeant for Synergy
Wells Fargo analyst David Maris says he asked Valeant Pharmaceuticals (VRX) whether industry speculation is true regarding the company losing 50-plus gastrointestinal salespeople to Synergy Pharmaceuticals (SGYP) following the latter's recent FDA approval. Valeant indicated that a number of salespeople have left but would not confirm how many, Maris tells investors in a research note. The analyst adds that Synergy would only comment that it has been very successful in hiring a large number of experienced salespeople. The loss of 50-plus salespeople would be another setback to the Salix/gastrointestinal salesforce at a time when prescription trends on Xifaxan are already weak, Maris contends. The analyst also learned that the son of Valeant CEO Joseph Papa joined Valeant in September 2016 as a product manager for Xifaxan, the company's largest product. Maris says Valeant acknowledged that several investors have already raised the matter. Maris has an Underperform rating on the shares, which closed the trading day down 4c to $16.35.
02/24/17
WELS
02/24/17
NO CHANGE
WELS
Wells says new Valeant is not new, calls shares overvalued
The market is underestimating Valeant Pharmaceuticals' "poor" prescription trends, reliance on price, employee turnover, execution risk on product launches, patent expiries including Xifaxan and numerous lawsuits, Wells Fargo analyst David Maris tells investors in a research note titled "Deja Valeant--We See History Repeating Itself." The stock is overvalued, and despite management wanting to talk about the "new Valeant," the company's business trends and pricing-driven model remain "old Valeant," Maris contends. He cut his Q4 earnings per share estimate for the company to $1.48 from $1.48, 2017 estimate to $5.03 from $5.14 and 2018 estimate to $5.45 from $5.91. His Q4 estimate remains well above the consensus of $1.22. Maris points out that since the new management team took over in 2016, Valeant set and then lowered guidance, raised prices on more than 50 products, missed key launch targets, had manufacturing issues and saw prescription declines continue. On the positive front, the company has sold $2.3B of assets, the analyst points out. Maris, who wrote this week that Valeant likely just lost 50-plus salespeople to Synergy Pharmaceuticals (SGYP), keeps an Underperform rating on Valeant with a $10-$13 price target range. The drugmaker closed yesterday at $16.58.

TODAY'S FREE FLY STORIES

10:30
11/23/17
11/23
10:30
11/23/17
10:30
General news
FX Action: EUR-USD, USD-JPY and other major pairings are in sideways mode »

FX Action: EUR-USD,…

DE

Deere

$145.25

6.02 (4.32%)

09:53
11/23/17
11/23
09:53
11/23/17
09:53
Upgrade
Deutsche Bank gets off sidelines, upgrades Deere shares to Buy »

Deutsche Bank analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

08:55
11/23/17
11/23
08:55
11/23/17
08:55
General news
FX Update: USD-CAD vaulted upwards on weak Canadian data »

FX Update: USD-CAD…

08:30
11/23/17
11/23
08:30
11/23/17
08:30
General news
FX Action: The USD index (DXY) logged a one-month low »

FX Action: The USD index…

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:08
11/23/17
11/23
08:08
11/23/17
08:08
Hot Stocks
Tesla CEO highlights 'record time' on Australian ion battery »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:07
11/23/17
11/23
08:07
11/23/17
08:07
Hot Stocks
Tesla completes construction on largest lithium ion battery in Australia »

The South Australian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

, INVA

Innoviva

$13.42

0.01 (0.07%)

07:56
11/23/17
11/23
07:56
11/23/17
07:56
Hot Stocks
GSK, Innoviva submit data to FDA for expanded Trelegy Ellipta label »

GlaxoSmithKline (GSK) and…

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

INVA

Innoviva

$13.42

0.01 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVM

Silvercorp Metals

$2.51

-0.07 (-2.71%)

07:52
11/23/17
11/23
07:52
11/23/17
07:52
Hot Stocks
Silvercorp Metals to buy back up to 5% of shares »

Silvercorp Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$10.00

-0.1 (-0.99%)

07:49
11/23/17
11/23
07:49
11/23/17
07:49
Hot Stocks
Cellcom Israel now second layer company according to Concentration Law »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GASS

StealthGas

$4.07

0.36 (9.70%)

07:06
11/23/17
11/23
07:06
11/23/17
07:06
Recommendations
StealthGas analyst commentary at Jefferies »

StealthGas trades at only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$41.01

4.31 (11.74%)

07:02
11/23/17
11/23
07:02
11/23/17
07:02
Recommendations
Copart analyst commentary at Jefferies »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DE

Deere

$145.25

6.02 (4.32%)

06:56
11/23/17
11/23
06:56
11/23/17
06:56
Upgrade
Deere rating change at Deutsche Bank »

Deere upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DE

Deere

$145.25

6.02 (4.32%)

06:55
11/23/17
11/23
06:55
11/23/17
06:55
Recommendations
Deere analyst commentary at Wells Fargo »

Deere price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

06:40
11/23/17
11/23
06:40
11/23/17
06:40
General news
FX Update: The dollar has remained on a weakening track »

FX Update: The dollar has…

SECO

Seeco Holding

$8.34

0.14 (1.71%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Seeco Holding management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Deutsche Bank to hold a conference »

Thailand SET Corporate…

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

04:25
11/23/17
11/23
04:25
11/23/17
04:25
General news
FX Action: USD-CAD punched out a 10-day low »

FX Action: USD-CAD…

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.